Compound tracker
MDMA.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.
N/A / Phase 1 / Phase 2 / Phase 3
Phases tracked
Active / Completed / Recruiting
Statuses seen
Trial rows
NCT06905652 Phase 1 Completed updated May 15, 2026
- Condition
- Healthy volunteers
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Jul 29, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: registry/basic-science pharmacology tracker only; healthy-volunteer completion does not establish PTSD efficacy, approval, label, reimbursement, access, or broad safety. Registry: completed Phase 1 randomized triple-masked placebo-controlled 3-period crossover; actual n=26; 300mg R-MDMA vs 100mg S-MDMA vs placebo; primary outcome subjective drug effects on visual analogue scales across study days; completion date 2026-05-12.
NCT07584720 Phase 1 Recruiting updated May 13, 2026
- Condition
- Healthy Volunteers
- Sponsor / institution
- Resilient Pharmaceuticals
- Start date
- Apr 23, 2026
Tracker note / source boundary
ClinicalTrials.gov v2 verification on 2026-05-14 | Overall status: RECRUITING | Enrollment: estimated n=32 | Lead sponsor: Resilient Pharmaceuticals | Collaborator: Dr. Vince Clinical Research | Intervention: Midomafetamine HCl | Tracker posture: Phase 1 healthy-volunteer PK/PD/ECG/cardiac-safety characterization; not PTSD efficacy/access.
NCT04030169 Phase 2 Completed updated Jan 28, 2025
- Condition
- PTSD
- Sponsor / institution
- MAPS Europe B.V.
- Start date
- Jun 24, 2020
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: MAPS Europe B.V. | Conditions: PTSD
NCT06044675 Phase 2 Recruiting updated Nov 26, 2024
- Condition
- Post Traumatic Stress Disorder
- Sponsor / institution
- Remedy
- Start date
- Nov 15, 2024
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 2 | Lead sponsor: Remedy | Conditions: Post Traumatic Stress Disorder
NCT04438512 N/A Stopped updated Nov 5, 2024
- Condition
- Post Traumatic Stress Disorder
- Sponsor / institution
- Lykos Therapeutics
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: NO_LONGER_AVAILABLE | Exact phase: Not listed | Lead sponsor: Lykos Therapeutics | Conditions: Post Traumatic Stress Disorder
NCT05948683 Phase 1 Completed updated Aug 19, 2024
- Condition
- MDMA ('Ecstasy'), Social Interaction
- Sponsor / institution
- University of Chicago
- Start date
- Jul 21, 2023
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Early Phase 1 | Lead sponsor: University of Chicago | Conditions: MDMA ('Ecstasy'); Social Interaction
NCT03790618 Phase 1 Completed updated Jan 5, 2024
- Condition
- Healthy, MDMA ('Ecstasy')
- Sponsor / institution
- University of Chicago
- Start date
- Jun 1, 2016
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University of Chicago | Conditions: Healthy; MDMA ('Ecstasy')
NCT06189027 Phase 3 Active updated Jan 3, 2024
- Condition
- PTSD
- Sponsor / institution
- University of Southern California
- Start date
- Nov 20, 2018
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: UNKNOWN | Exact phase: Phase 3 | Lead sponsor: University of Southern California | Conditions: PTSD
NCT04516902 Phase 1 Completed updated Aug 23, 2022
- Condition
- Healthy
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Jan 1, 2021
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Healthy
NCT01270672 N/A Completed updated Dec 11, 2018
- Condition
- Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Not applicable | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders
NCT00252174 Phase 2 Stopped updated Nov 14, 2017
- Condition
- Anxiety Disorder, Cancer
- Sponsor / institution
- Brigham and Women's Hospital
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: Brigham and Women's Hospital | Conditions: Anxiety Disorder; Cancer
NCT01447472 Phase 1 Completed updated Oct 6, 2011
- Condition
- Metabolism, Interaction
- Sponsor / institution
- Parc de Salut Mar
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: Parc de Salut Mar | Conditions: Metabolism; Interaction
Related updates
May 15, 2026 Publication Research
PubMed PMID 41633448 / Journal of Affective Disorders reports a framework-guided qualitative analysis of 21 interviews with Australian clinicians, researchers, and patients after Australia rescheduled MDMA to permit authorized prescribing for PTSD outside clinical trials; intended to inform guideline development.
Source/tracker note
Last checked 2026-05-15 UTC. Claim boundary: qualitative implementation/guideline-context evidence only; not an efficacy trial, not a broad safety finding, and not evidence of approval/access outside the Australian authorized-prescribing context described by the article.
May 12, 2026 Trial Update Company
AtaiBeckley company release says BPL-003 Phase 3 ReConnection remains on track for Q2 2026, with ReConnection-1 ~350 and ReConnection-2 ~230, MADRS Week 4 primary, and 52-week OLE; VLS-01 Phase 2 Elumina topline is anticipated Q4 2026; EMP-01 oral R-MDMA Phase 2a in SAD showed company-described convergent improvements; cash/securities were $209.9M with runway into 2029.
Source/tracker note
Last checked 2026-05-16 UTC. Claim boundary: company-reported pipeline/capitalization and Phase 3-design tracker only; not approval, label, reimbursement, access, independent efficacy/safety confirmation, or proof that planned Phase 3 studies will start/succeed. Keep BPL-003, VLS-01, and EMP-01 separate from unrelated CNPV/company-primary-pending items.
May 11, 2026 Publication Research
PubMed PMID 42114863 / BMJ Open article describes development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET) via Delphi process. Track as safety/tolerability measurement infrastructure, not efficacy evidence or regulatory approval.
Source/tracker note
PubMed page checked 2026-05-14; DOI 10.1136/bmjopen-2025-105630. Guardrail: tool-development/publication item only; does not establish MDMA-assisted therapy safety, efficacy, approval, or access.
Mar 31, 2026 Trial Update MAPS Official
Source/tracker note
Additional safety monitoring completed on 200+ subjects in expanded Phase 3 cohorts. No serious adverse events reported. Efficacy trends continue to match primary trial data.
Mar 30, 2026 Trial Update MAPS Official
Source/tracker note
Latest enrollment numbers and safety data from Phase 3 MDMA-assisted psychotherapy trials show positive outcomes.
Conditions touched
Anxiety Disorder, CancerHealthyHealthy volunteersHealthy VolunteersHealthy, MDMA ('Ecstasy')MDMA ('Ecstasy'), Social InteractionMetabolism, InteractionMood Disorder, Substance-Related Disorders, Amphetamine-Related DisordersPost Traumatic Stress DisorderPTSD